Editorial Podcasts

AstraZeneca reported consistent Phase III results for its IL-33 biologic in COPD, while Boehringer Ingelheim continues expanding its use of AI to accelerate drug discovery and disease research. Meanwhile, the FDA has accepted a biologics license application for Gazyva as a potential treatment for systemic lupus erythematosus, signaling progress in addressing unmet patient needs.

ADC cleaning validation requires risk-based strategies to manage degradation and ensure safe limits for highly potent, dual-modality therapeutics, says Paul Lopolito, STERIS’ director of Technical Services, at INTERPHEX 2026.

Long-term survival data, scalable cell engineering approaches, and perioperative immunotherapy strategies are highlighted in today’s podcast, which explores how these efforts are leading to evolving endpoints and access-focused oncology development.

A look inside our latest issue of BioPharm International, where we explore how the biopharma industry is leaning into technical innovation while remaining grounded in operational discipline.

Today’s podcast talks about RNA therapy optimization, AI-driven development, and collaborative models improving efficiency, scalability, and long-term outcomes.

Today’s podcast spotlights major funding and a high-profile deal surrounding emerging multispecific immune-engaging biologics that demonstrate improved targeting precision and safety control across complex oncology and autoimmune indications.

The episode explores how regulatory signals across drug approvals, trade policy, AI governance, and drug pricing shape business strategy and investor decisions before formal rules are ever finalized.

Today’s podcast dives into Series A funding for T‑cell engagers and the advancement of multi-agonist metabolic therapies, which highlight innovation and platform-driven strategies in current biopharma pipelines.

Today’s podcast explores how late-stage clinical evidence supports extending established biologics into adjacent inflammatory diseases, reinforcing platform-based development strategies.

In today’s podcast, integrated biomarker modeling and dual-pathway immune checkpoint modulation highlight evolving strategies to improve translational efficiency and durability in oncology trials.

INOVIO and Akeso’s combination of DNA tumor antigen priming and dual checkpoint inhibition exemplifies adaptive trial strategies for challenging glioblastoma therapy.

The episode will explore structural implications for supply chains, distribution models, and international strategy—not a political discussion, but a forward-looking planning lens.

Today’s podcast covers how integrated development models and multi-pathway therapeutic design are signaling a shift toward scalable, system-ready biopharma innovation and translational efficiency.

Clinical trial execution and workforce strategy emerge as critical drivers of successful rare disease and advanced therapy development outcomes.

Today’s podcast highlights how sustained clinical efficacy data in alpha-thalassemia and ulcerative colitis highlight durability as a defining benchmark in modern biologic drug development.

Welcome to BioPharm Brief, a new podcast that synthesizes BioPharm International®’s coverage into concise, insight-driven updates on biopharmaceutical research, clinical and drug development trends, and evolving industry strategies.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

Learn Morewww.bio-rad.com/fluvaccine

Dennis Brandl, President, at BR&L Consulting, spoke with BioPharm International about what should be expected when transitioning from paper to EBR.

Don Frail, Vice President, AstraZeneca Innovative Medicines Group discusses the company's approach to innovation and the upcoming session at the BIO International Convention

A conversation with Armand Keating, the Epstein Chair in Cell Therapy and Transplantation at the University of Toronto prior to his presentation at Bio 2013

In recent years, large pharmaceutical companies have launched a variety of initiatives to restock ailing pipelines and boost business performance including mergers and acquisitions, diversifying business portfolios to non-pharmaceutical products, downsizing, spinoffs, and entering the biopharmaceutical arena.

BioPharm International interviews Tarja Mottram, CEO of Action for Results, on the marriage of science and business to ensure sustainable growth. Posted Feb. 2012.

Mike Ultee, chief scientific officer of Laureate Biopharmaceutical Services, discusses advances in separations technology, beginning with the 1988 publication of ?Separations Technology Outlook, Part II? by Nancy E. Pfund and Kathleen G. Charles.